Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It seems to me nobody is taking care the website, it is a mess.
Advaxis no longer on Amgen website, Advaxis should do the same, taking down Amgen from website, misleading investors
https://www.amgenscience.com/features/the-shape-of-drugs-to-come/
lot of M&A going to happen with biotech companies this year, good start with BMY and CELG. Be optimistic!
Wow !Drugmaker Bristol-Myers to buy Celgene for $74 billion
https://finance.yahoo.com/news/drugmaker-bristol-myers-buy-celgene-122832433.html
Is it a coincidence that R&D chief Sean Harper left? we all know He was the guy behind the collaboration.
Happy New Year! Hope this is the year for biotech stock and Advaxis! Reverse split is not that scary,with good science and data, anything is possible! now we have to reset target price for buyout with RS to $100-$150. have faith guys!
what if PPS will gone up to $2.00 before FEB 21st annual meeting, is RS still on the table?
From 14A filing,
The Board has adopted a resolution approving and recommending to the Company’s stockholders for their approval a proposal to amend our certificate of incorporation to effect a reverse split of our outstanding shares of common stock within a range of one share of common stock for every ten shares (1-for-10) of common stock to one share of common stock for every twenty-five shares (1-for-25) of common stock, with the exact reverse split ratio to be decided and publicly announced by the Board prior to the effective time of the amendment to our Amended and Restated Certificate of Incorporation to effect the reverse stock split (the “Reverse Stock Split Amendment”). If the stockholders approve this Proposal No. 3, the Board will have the authority to decide, at any time prior to the date of our 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”), whether to implement the reverse stock split and the precise ratio of the reverse stock split within a range of one-for-ten shares of our common stock to one-for-twenty-five shares of our common stock. If the Board decides to implement the reverse stock split, the reverse stock split will become effective upon the filing of the Reverse Stock Split Amendment with the Secretary of State of the State of Delaware.
The Board reserves the right, even after stockholder approval, to abandon or postpone the filing of the Reverse Stock Split Amendment if the Board determines that it is not in the best interests of the Company and the stockholders. If the Reverse Stock Split Amendment is not implemented by the Board prior to the date of the 2020 Annual Meeting, the proposal will be deemed abandoned, without any further effect. In that case, the Board may again seek stockholder approval at a future date for a reverse stock split if it deems a reverse stock split to be advisable at that time.
The form of the Reverse Stock Split Amendment is attached to this Proxy Statement as Appendix A. The following discussion is qualified in its entirety by the full text of the Reverse Stock Split Amendment, which is incorporated herein by reference.
Reasons for the Reverse Stock Split
The primary reason for the reverse stock split is to allow us to attempt to increase the bid price of our common stock by reducing the number of outstanding shares of our common stock. To continue listing on The Nasdaq Global Market, we must comply with the applicable listing requirements under NasdaqNasdaq Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share. On December 10, 2018, the closing bid price of our common stock on the NasdaqNasdaq Global Market was $0.37. The Board believes that the reverse stock split will enhance the Company’s ability to maintain compliance with the applicable listing requirements under NasdaqNasdaq Marketplace Rules.
If we were unable to maintain compliance with the $1.00 minimum bid price requirement and our common stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the Pink Sheets or the OTC Bulletin Board. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules regarding “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital.
In addition, among the factors considered by the Board in reaching its decision to recommend the reverse stock split, the Board considered the potential effects of having stock that trades at a low price. Since the brokerage commissions on stock with a low trading price generally represent a higher percentage of the stock price than commissions on higher priced stock, investors in stocks with a low trading price pay transaction costs (commissions, markups, or markdowns) at a higher percentage of their total share value, which may limit the willingness of individual investors and institutions to purchase our common stock.
Reverse split is not the end, I had a stock after RS, stock price went up to from $5 to $40, i made $200K profit.
If Advaxis science and data is not a scam, with good management,and enough cash, we might see sunshine and still possible a buyout in near future. overall market is a mess now with biotech.
If everything is a legally scam and lie from beginning,and company lied to investors and their partners. then it is over with this company. BOD was on purpose to hire KEN to shutdown advaxis based on his past. He is being used by BOD! JMHO
not much money left, they dont care
Anybody live near Advaxis office? I would drive by to see what's going at the headquarter. Is the parking lot empty?
They took down all jobs on the website and linkedin, strange to me, very quiet.
I'm prepared for the worst and best in 2019!
Astrazenecca lung cancer failed
Bristol-Myers lung cancer failed
merck&incyte lung cancer failed
Merck KGaA &pfizer lung cancer failed
Roche lung cancer failed to meet Merck standard
we may have a winner! Lots of possibilities here!
Just read this again!
Fourteen Years After Lung Cancer Diagnosis, Patient is Enjoying Her Life
http://www.hadassah.org/news-stories/lung-cancer.html
In 2008, Tempkin was a year beyond the five-year survival measure, but she still had lung cancer. As it happens, clinical trials were going on at Hadassah using the Listeria bacteria as a cancer vaccine, taking advantage of the bacteria's ability to induce immunity. Although there was no clinical proof that it could impede metastasizing lung cancer, Tempkin was able to get the vaccine on a compassionate basis, through the connections of the Hadassah researchers. It worked for her. "We can't prove why it worked for her and not other patients," said Dr. Nechushtan. "The vaccine may have improved her body's response to more traditional cancer treatment." In Israel, the listeria vaccine was only available at Hadassah Hospital.
This could explains why Amgen cancels deal with Advaxis
https://www.fool.com/investing/2018/12/19/forget-bluebird-bio-amgen-is-a-better-biotech-stoc.aspx
check out advaxis instagram, they are playing everyday.
Amgen updated their website about a month ago, why keep advaxis on the site if they knew NEO was not working, do you think Amgen just realized last week?
Amgen’s Growing Immunotherapy Arsenal
https://www.amgenscience.com/features/amgens-growing-immunotherapy-arsenal/
If you see AGENs deal today, you will know how much NEO and HOT could get.
Agenus stock shoots up 60% after announcing drug development deal with Gilead
https://www.marketwatch.com/story/agenus-stock-shoots-up-60-after-announcing-drug-development-deal-with-gilead-2018-12-20?siteid=yhoof2&yptr=yahoo
37th Annual J.P. Morgan healthcare conference is coming, I hope Ken is going January 7 - 10, 2019
Westin St. Francis Hotel | San Francisco, California
SEC approves rule requiring companies to disclose whether executives and directors can hedge against declines in their companies’ stock
Companies Must Disclose Executive Hedging Strategies
https://www.wsj.com/articles/companies-must-disclose-executive-hedging-strategies-11545180777?mod=e2tw
agree!
Amgen collaborate with lots of small bio companies, this is not the reason
Kite deal, but Gilead bought for $12 billion
Kite to Receive a $60 Million Upfront Payment From Amgen and Eligible for up to $525 Million in Regulatory and Sales Milestone Payments per Amgen Program; Plus, Tiered High Single- to Double-Digit Royalties for Sales and License of Kite's Intellectual Property for CAR T Cell Products
cytomX deal
Amgen will make an upfront payment of $40 million and purchase $20 million of CytomX common stock. CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for the EGFR program. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S.
Immatics deal
The deal—which sees Immatics get a $30 million upfront payment and could net it more than $1 billion in milestones—focuses on developing double-headed (bispecific) antibodies that wil
Under the terms of the agreement, Aduro will receive an upfront payment of $12 million and will be eligible for development and commercial milestones up to approximately $620 million per product, as well as royalty payments in the single to low-double digits should Lilly successfully commercialize a therapy from the collaboration. Aduro will receive research funding during the research term and has the option to co-fund the clinical development of each product in exchange for an increase in royalty payments. Lilly will be responsible for all costs of global commercialization.
Wow, the game just started with Advaxis.
Anybody got message from IR?
Major layoff expected after new year! IMO
Is it normal for Amgen and Advaxis not to issue a PR regarding the termination?
Read article from Richard pearson 2015 Again, do you guys think he was right?
Advaxis: Heavily Promoted And Misleading Investors
https://seekingalpha.com/article/2836026-advaxis-heavily-promoted-and-misleading-investors
Ops I did it again! on the brink of ruin
what a shame to read this article again!
A biotech firm, on the brink of ruin, resurrects itself via man — and microbe
https://www.statnews.com/2016/08/22/advaxis-amgen-cancer-listeria/
save the best for the last!
2018 AACR NEO summary, are all of these science bull$hit scam?
• ADXS-NEO controls tumor growth by targeting NSMs expressed as 21-mers in Listeria monocytogenes bacterial vector
• ADXS-NEO can control tumor growth and generate neoantigen-specific CD8+ T cells by targeting neoantigens that fail to
elicit immunogenicity when immunized as peptide + CpG adjuvant
• ADXS-NEO immunotherapy platform is a potent inhibitor of the suppressive TME, by reducing numbers and suppressive phenotype of Tregs, MDSCs, and TAMs
• ADXS-NEO generates a robust accumulation of cytotoxic and neoantigen-specific CD8+ T cells that control tumor g
2018 AACR HOT summary, are these the reasons NEO terminated?
•Lm-HOT therapy enhanced antitumor efficacy and improved long-term survival.
• Lm-HOT therapy increased tumor-specific T cells and significantly decreased tumor-resident
Tregs.
• ADXS-503 therapy delays tumor growth similar to that of the KRAS_G12D_21mer Construct.
• ADXS-503 elicits effective anti-tumor immunity whether it is in a single or multi-target construct.
• ADXS-HOT platform is a promising approach to target shared hotspot mutations.
Remember the deal Aduro made with Novartis $200 million up front
I'm wondering what Novartis is thinking after Amgen terminated with Advaxis
Under the agreement, Novartis is paying $200 million up front to kick off a collaboration on small-molecule therapies that target a pathway called STING, or stimulator of interferon genes. Aduro's preclinical candidates are cyclic dinucleotides--chemicals naturally expressed by bacteria and immune cells--that stimulate a STING response and thereby help the body's natural defenses better recognize and attack tumors, the company said.
If Amgen terminated the deal not because of Data, then the ball is at Advaxis hand!
Very strange to see Amgen terminated the deal before HOT trial is starting this month. NEO was just started and Data not even ready yet. You really don't see this kind of things happen in the middle of Phase 1 trial.
I'm sure KEN knew this already before the last conference. we will know by next week.
Just because no milestone payment any time soon, the deal collaped. also because of HOT for NSCLC.
yes vanguard new increased position
https://www.sec.gov/Archives/edgar/data/102909/000095012318012369/xslForm13F_X01/form13fInfoTable.xml
Now NEO and HOT together could worth more than $1 Billion, why Amgen not buying it?